Menu
No results found.
Weekly Share Price & Valuation Overview
Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 471.62M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 880.42M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 851.60M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 480.20M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 216.80M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 15.79
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 2.62
- Shares Outstanding
- 53.35M
- Float Shares
- 48.25M
- Implied Shares Outstanding
- 53.35M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
0.35%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
25.46%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
56.39%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
16.38%
- ROA Return on assets: net income ÷ total assets.
-
5.03%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
30.24%
- Revenue Growth Year-over-year revenue growth.
-
-44.70%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.73
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.26
- Total Cash Cash and equivalents.
- USD 267.30M
- Total Debt Short + long-term interest-bearing debt.
- USD 676.10M
- Net Debt Total debt − cash (negative = net cash).
- USD 408.80M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 3.12
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 169.00M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 227.64M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
19.84%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
26.73%
- Cash Conversion (OpCF/EBITDA)
- 0.78
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.